R & D

The CRUK-CRT- Abcodia Early Diagnosis Consortium

The Early Diagnosis Consortium is a strategic alliance focusing on discovering novel biomarkers for the earlier diagnosis of cancers for which there are currently limited screening tests available; non-small cell lung, colorectal and pancreatic cancer. The partnership combines Cancer Research UK’s extensive clinical oncology and scientific network with Abcodia’s expertise in the longitudinal profiling of biomarkers. After a successful pilot phase, discovery experiments have been initiated in proteomics, autoantibody and microRNA technology platforms.

Testing blood samples for pancreatic cancer biomarkers.

Pancreatic Cancer

Pancreatic cancer is the only cancer with a predicted worsening mortality trend in Europe and the 5-year survival is only 3%. Abcodia is developing an algorithm-based test for the screening of individuals at high risk of pancreatic cancer in collaboration with Professor Carlo Berzuini, Professor of Biostatistics at The University of Manchester. Abcodia secured a grant from the European Commission’s Horizon 2020 programme to progress this project.

Testing blood samples for lung cancer biomarkers.

Lung Cancer

Abcodia has a collaboration with Dr Phil Crosbie and Professor Tony Whetton of The University of Manchester for state-of-the-art SWATH proteomics studies on a cohort of lung cancer cases with the aim of discovering new blood-based biomarkers for earlier detection of the disease.

If you are interested in exploring whether Abcodia’s expertise in longitudinal biomarker studies, using the UKCTOCS human serum biobank for earlier detection of disease could help with your biomarker studies, contact us.

Get Our Biobank Brochure

Learn how the Serum Biobank is creating opportunities for advancing biomarkers for screening and early diagnosis.